NCT04131569

Brief Summary

Antimicrobial resistance is a major threat worldwide and extended-spectrum beta-lactamase producing Enterobacteriales (ESBL-E) are a leading cause because of their wide dissemination. Gut microbiota seems to be correlated with multi-drug resistant organism carriage. This study thus aims to analyse the correlation between gut microbiota, ESBL-E fecal carriage and subsequent infection.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 15, 2019

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

October 16, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 18, 2019

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 15, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2020

Completed
Last Updated

October 21, 2019

Status Verified

October 1, 2019

Enrollment Period

5 months

First QC Date

October 16, 2019

Last Update Submit

October 17, 2019

Conditions

Keywords

ESBL-Efecal carriagemicrobiotanosocomial infection

Outcome Measures

Primary Outcomes (1)

  • Gut bacteriobiota diversity according to ESBL specie

    Comparison of gut bacteriobiota alpha diversity between ESBL E. coli and ESBL K. pneumoniae fecal carriers

    at positive screening

Secondary Outcomes (13)

  • Gut mycobiota diversity according to ESBL specie

    at positive screening

  • Gut bacteriobiota diversity according to ESBL specie

    at positive screening

  • Gut mycobiota diversity according to ESBL specie

    at positive screening

  • bacteria and the absence of ESBL E. coli fecal carriage

    at admission

  • fungi and the absence of ESBL E. coli fecal carriage

    at admission

  • +8 more secondary outcomes

Other Outcomes (2)

  • Association of gut bacteriobiota with ventilator-associated pneumonia

    at admission

  • Association of gut bacteriobiota with intensive care unit mortality

    at admission

Study Arms (2)

ESBL-E fecal carriers

Patients with a positive ESBL-E fecal carriage according to routine screening

Diagnostic Test: ESBL-E fecal carriage screening according to routine care

non ESBL-E fecal carriers

Patients without positive ESBL-E fecal carriage according to routine screening

Diagnostic Test: ESBL-E fecal carriage screening according to routine care

Interventions

ESBL-E fecal carriage screening according to routine care

ESBL-E fecal carriersnon ESBL-E fecal carriers

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Every in-patients admitted to our medical intensive care unit

You may qualify if:

  • Patient above 18 year-old admitted to intensive care unit
  • ESBL-E fecal carriage according to current screening recommendations for ESBL-E carriage group
  • Feces quantity on rectal swab adequate for routine screening and microbiota analysis

You may not qualify if:

  • Guardianship, curatorship, or prisoners
  • No health insurance
  • No legal representative

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical intensive care unit, Pelelgrin hospital

Bordeaux, Nouvelle-Aquitaine, 33000, France

RECRUITING

Related Publications (1)

  • Prevel R, Enaud R, Orieux A, Camino A, Sioniac P, M'Zali F, Dubois V, Berger P, Boyer A, Delhaes L, Gruson D. Bridging gut microbiota composition with extended-spectrum beta-lactamase Enterobacteriales faecal carriage in critically ill patients (microbe cohort study). Ann Intensive Care. 2023 Apr 4;13(1):25. doi: 10.1186/s13613-023-01121-0.

Biospecimen

Retention: SAMPLES WITHOUT DNA

rectal swabs

MeSH Terms

Conditions

Communicable DiseasesCritical IllnessCross Infection

Condition Hierarchy (Ancestors)

InfectionsDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsIatrogenic Disease

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

October 16, 2019

First Posted

October 18, 2019

Study Start

October 15, 2019

Primary Completion

March 15, 2020

Study Completion

March 15, 2020

Last Updated

October 21, 2019

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will not share

Locations